Eigene Publikationen
Everding S, Römer S, Bohn A, Holz E, Lieder F., Baumgart P, Loyen M, Waltenberger J, Lebiedz P. Clinical practice of systemic lysis in prehospital resuscitation : Success and
complication rates. Med Klin Intensivmed Notfmed. 2015 Sep;110(6):445-51
Lawrenz T., Borchert B., Leuner C., Bartelsmeier M., Reinhardt J., Strunk-Mueller C., Meyer Zu Vilsendorf D., Schloesser M., Beer G., Lieder F., Stellbrink C., Kuhn H.
Endocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy; Acute Results and 6 Months’ Follow-Up in 19 Patients. J Am Coll Cardiol. 2011 Feb 1;57(5):572-6
H. Kuhn, T. Lawrenz, F. Lieder, C. Leuner, C. Strunk-Mueller, L. Obergassel, M. Bartelsmeier, C. Stellbrink. Survival after transcoronary ablation of septal hypertrophy in
hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol 2008;97:234–243
T. Lawrenz, F. Lieder, M. Bartelsmeier, C. Leuner, A. Feuchtl, B. Borchert, D.Meyer zu Vilsendorf, C. Strunk-Muller, A. Feuchtl, J. Reinhard C., Stellbrink, H. Kuhn. Predictors
of complete heart block after transcoronary ablation of septal hypertrophy: Results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive
cardiomyopathy. J Am Coll Cardiol. 2007;49 (24):2356-63
L. Obergassel, T. Lawrenz, F. H. Gietzen, F. Lieder, C. Leuner, H. Kuhn, C. Stellbrink. Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic
obstructive cardiomyopathy associated with atrial fibrillation. Clin Res Cardiol 2006;95:254– 260
Lawrenz T., Obergassel L., Lieder F., Kuhn H. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic
obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2005 Apr;28(4):295-300
Breithardt OA, Beer G, Stolle B, Lieder F., Franke A, Lawrenz T, Hanrath P, Kuhn H. Mid systolic septal deceleration in hypertrophic cardiomyopathy: clinical value and insights
into the pathophysiology of outflow tract obstruction by tissue Doppler echocardiography. Heart. 2005 Mar;91(3):379-80
Lawrenz T., Beer G., Lieder F., Kuhn H. Katheterinterventionelle Therapie der Hypertrophisch Obstruktiven Kardiomyopathie (HOCM). Cardiovasc 2004;4 (6) 24-32
Kuhn H, Lawrenz T, Lieder F., Gietzen FH, Obergassel L, Strunk-Mueller C, Stolle B, Leuner C. Alcohol Septal Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy.
In: Maron B (ed) Diagnosis and Treatment of Hypertrophic cardiomyopathy. Blackwell Publishing 2004; 279-296
Kuhn H., Gietzen F., Leuner C., Schafers M., Schober O., Strunk-Muller C., Freick M., Gockel B., Lieder F., Raute-Kreinsen U. Transcoronary ablation of septal hypertrophy (TASH):
a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol.
T. Lawrenz, C. Leuner, M. Bartelsmeier, M. Schloesser, F. Lieder, C. Stellbrink, H. Kuhn. Survival after transcoronary ablation of septal hypertrophy (TASH): Follow-up of 644
consecutive patients with severe HOCM. Clin Res Cardiol 99 (2010)1718
T. Lawrenz, C. Leuner, M. Bartelsmeier, M. Schloesser, F. Lieder, C. Stellbrink, H. Kuhn. Survival of 644 consecutive patients with severe HOCM after transcoronary ablation of
septal hypertrophy (TASH). A single centre experience. European Heart Journal (2009); 30:23
T. Lawrenz, F. Lieder, M. Bartelsmeier, C. Leuner, A. Feuchtl, B. C. Stellbrink, H. Kuhn. ranscoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive
cardiomyopathy: Studies in infarction markers in the early post TASH setting. Clin Res Cardiol 96: Suppl 1 (2007):888
T. Lawrenz, F. Lieder, M. Bartelsmeier, C. Leuner, A. Feuchtl, B. Borchert, C. Stellbrink, H. Kuhn. Prognosis after transcoronary ablation of septal hypertrophy: long-term
follow-up data in 604 patients with hypertrophic obstructive cardiomyopathy. European Heart Journal 2006;Vol.27:3196
T. Lawrenz, F. Lieder, M. Bartelsmeier, C. Leuner, A. Feuchtl, B. Borchert, C. Stellbrink, H. Kuhn. Endocardial radiofrequency ablation of septal hypertrophy for hypertrophic
obstructive cardiomyopathy: acute results and 6 months follow-up in 13 patients. European Heart Journal 2006;Vol.27:3197
F. Lieder, T. Lawrenz, C. Leuner, H. Kuhn, Ch. Stellbrink. Eliminierung von Synkopen bei Patienten mit hypertrophisch obstruktiver Kardiomyopathie nach erfolgreicher
katheterinterventioneller Therapie – Bedeutung der Erholungsphase der Ergometrie. Z Kardiol 94 (2005):299
F. Lieder, T. Lawrenz, C. Leuner, H. Kuhn, Ch. Stellbrink. Symptomatische skelettale Myopathie bei Patienten mit Hypertrophischer Kardiomyopatie (HCM) - Zufallsbefund oder
wegweisendes Symptom?. Z Kardiol 94 (2005):300
F. Lieder, T. Lawrenz, M. Bartelsmeier, G. Beer, H. Kuhn. Symptomatic skeletal myopathy in patients with hypertrophic cardiomyopathy: incidental finding or leading clinical
symptom? European Heart Journal 2005;Vol.26:444
T. Lawrenz, F. Lieder, Chr.Leuner, L.Obergassel, D.Meyer zu Vilsendorf, C.Strunk-Müller, G.Beer, H.Kuhn. Alkohol-Dosisfindungsstrategie bei der Katheterbehandlung der HOCM durch
transkoronare Ablation der Septumhypertrophie (TASH): Eine vergleichende Analyse bei 583 Prozeduren. Z Kardiol 94 (2005):145
T. Lawrenz, F. Lieder, M. Bartelsmeier-Schmale, C. Leuner, G. Beer, C. Stellbrink, H. Kuhn. Prediction of total heart block after transcoronary ablation of septal hypertrophy:
results of electrophysilogic investigation in 140 HOCM-patients European Heart Journal 2005;Vol.26:267
T. Lawrenz, F. Lieder, M. Bartelsmeier-Schmale, G. Beer, C. Leuner, C. Stellbrink, H. Kuhn. Transcoronary ablation of septal hypertrophy for HOCM: lower dosages of ethanol reduce
the size of the septal defect and lead to the same clinical and haemodynamic improvement European Heart Journal 2005;Vol.26(Supplement):560
T. Lawrenz, F. Lieder, G. Beer, J. Reinhard, M. Bartelsmeier-Schmale, S. Röthemeier, Chr. Leuner, L. Obergassel, C. Strunk-Müller, D. Meyer zu Vilsendorf, H. Kuhn. Akutergebnisse
der Endokardialen Radiofrequenzablation zur Behandlung der hypertrophisch obstruktiven Kardiomyopathie HOCM). Z Kardiol 94: Suppl 1 (2005):146
T. Lawrenz, F. Lieder, C. Strunk-Müller, D. Meyer zu Vilsendorf, Chr. Leuner, L. Obergassel. Arioventricular conduction disturbances during transcoronary ablation of septal
hypertrophy (TASH): results of simultaneous electrophysiologic investigation in 105 prospective HOCM patients. Z Kardiol 94: Suppl 1 (2005):890
T. Lawrenz, M. Bartelsmeier-Schmale, S. Röthemeier, F. Lieder, L. Obergassel, Chr. Leuner, H. Kuhn. Untersuchung der Defektzone nach gekühlter endokardialer Radiofrequenzablation
der Septumhypertrophie (ERASH) bei hypertrophisch obstruktiver Kardiomyopathie (HOCM) mittels Kardio-MRT. Z Kardiol 94: Suppl 1 (2005):915
F. Lieder, T. Lawrenz, Chr.Leuner, L.Obergassel, G.Beer, H.Kuhn. Katheterinterventionelle Behandlung der HOCM - hämodynamische Effekte eines 'low alcohol dose' - Regime. Z
Kardiol(93)2004:435
F. Lieder, T. Lawrenz, L.Obergassel, Chr.Leuner. Erhebliche Reduktion der Arryhthmogenität bei der katheterinterventionellen Therapie der HOCM durch Anwendung geringer
Alkoholmengen ('low alcohol dose' - Regime). Z Kardiol. (93) 2004:1048
G.Beer, T.Lawrenz, N.Stoevesandt, F. Lieder. Der klinische Nutzen der Myokardbiopsie bei Patienten mit hypertrophischer nicht obstruktiver Kardiomyopathie (HNCM). Z Kardiol. (93)
2004:435
T.Lawrenz, F. Lieder, L.Obergassel, Chr.Leuner, H.Kuhn. Reduktion der Alkoholmenge bei der Katheterbehandlung der HOCM: Einfluss des 'Low-Dose-Regimes' auf Prognose,
Komplikationsrate und klinischen Erfolg. Z Kardiol. (93) 2004:558
B. Stolle, O.-A. Breithardt, T. Lawrenz, F. Lieder, H. Kuhn. Normalisierung der septalen Longitudinalbewegung nach transkoronarer Ablation der Septumhypertrophie bei
hypertrophisch-obstruktiver Kardiomyopathie - Untersuchung mittels farbkodierter Gewebedoppler-Echokardiographie. Z Kardiol.(93) 2004:1388
G. Beer, O.A. Breithardt, T. Lawrenz, J. Reinhardt, F. Lieder, H. Kuhn. Die mittsystolische septale Dezeleration der septalen Longitudinalbewegung, ein neues Zeichen der
hypertrophischen obstruktiven Kardiomyopathie (HOCM) : Gewebedopplerechokardiographie vor und nach transkoronarer Ablation der Septumhypertrophie. Z Kardiol 93:5 (2004):89
F. Lieder, F. Gellerich, T. Lawrenz, G. Beer, HJ. Holzhausen, H. Kuhn. Skeletal myopathy with fiber type I predominance and ultrastructural abnormalities in patients with
hypertrophic obstructive cardiomyopathy European Heart Journal 2003;Vol.24:561
F. Lieder, Lawrenz T., Obergassel L., Gockel B., Beer G., Kuhn H. Abrupt coronary no-flow phenomenon in hypertrophic obstructive cardiomyopathy: no specific adverse effect of
alcohol injection in alcohol septal ablation. J Heart Disease; Vol 3 (1), (2003): 182
H. Kuhn, T. Lawrenz T., F. Lieder. Catheter based treatment for HOCM: Studies on myocardial infarction in a unique clinical infarct model. J Heart Disease Vol.2(1);
(2003):125
Lawrenz, F. Lieder, C. Leuner, L. Obergassel, F. Gietzen, C. Strunk-Mueller, D. Meyer zu Vilsendorf, H. Kuhn Transcoronary ablation of septal hypertrophy for hypertrophic
obstructive cardiomyopathy: studies of infarction markers and alcohol spill over European Heart Journal 2003;Vol.24:556
T. Lawrenz, F. Lieder, C. Leuner, L. Obergassel, B. Gockel, C. Strunk-Mueller, H. Kuhn. What is the correct amount of ethanol in the catheter based treatment for hypertrophic
obstructive cardiomyopathy? European Heart Journal 2003;Vol.24:136
F. Lieder, U. Elmendorf-Daut, C. Strunk-Mueller, T. Lawrenz, L. Obergassel, G. Beer, H. Kuhn. Abnormal heart rate and blood pressure behaviour after exercise in patients with
hypertrophic obstructive cardiomyopathy and recurrent syncope – normalization after catheter interventional treatment. European Heart Journal 2003;Vol.24:136
F. Lieder, T. Lawrenz, G. Beer, C. Leuner, L. Obergassel, C. Strunk-Mueller, H. Kuhn. Abrupt coronary no-flow phenomenon in hypertrophic obstructive cardiomyopathy: no specific
adverse effect of alcohol injection in alcohol septal ablation. European Heart Journal 2003;Vol.24:136
Lieder F., Lawrenz T., Gietzen F., Obergassel L., Leuner C., Kuhn H. Prognose nach Transkoronarer Ablation der Septum Hypertrophie (TASH): 98,8% Follow-up bei 329 behandelten
Patienten mit Hypertrophisch Obstruktiver Kardiomyopathie (HOCM). Z Kardiol. (92) 2003:523
Lawrenz T., Lieder F., Gietzen F., Goetsch U., Kuhn H. Prognosis of patients with hypertrophic cardiomyopathy after transcoronary ablation of septal hypertrophy. JACC 2003; Vol
41 (4):807-3
Lieder F., Gieztzen F, Holzhausen HJ, Gellerich FN, Kuhn H. Skeletal mitochondrial myopathy in patients with hypertrophic obstructive catdiomyopathy: an obstacle to successful
catheter interventionla treatment. JACC 2002; Vol 39: 2119
F. Lieder, F. Gietzen, C. Strunk-Mueller, L. Obergassel, C. Leuner, H. Kuhn. Complete relief of syncope during follow-up in patients with HOCM after successful catheter
interventional treatment European Heart Journal 2002; Vol 4:3739
T. Lawrenz, F. Gietzen, F. Lieder, L. Obergassel, H. Kuhn. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transcoronary ablation of septal hypertrophy
(TASH). European Heart Journal 2002; Vol 4,:3736
Lieder F., Gietzen F., Strunk-Mueller C., Beer G., Gockel B., Kuhn H. Impact of catheter interventional treatment of HOCM in patients with recurrent syncope. J Heart Failure Vol
7; (1); (2002):22
G. Beer, F. Gietzen, H.E. Gabbert, F. Lieder, H. Kuhn Incidental diagnosis of Fabrys disease in a patient with hypertrophic obstructive cardiomyopathy not responding to catheter
interventional therapy European Heart Journal Volume 22, 2001
H. Kuhn, F.H. Gietzen, G. Breithardt, F.R. Röhrig, F. Lieder, U. Götsch, H.D. Schulte, M. Freick Pacemaker therapy and alcohol ablation for HOCM: a randomized study. European
Heart Journal Volume 22, 2001
Lieder F., Gietzen FH, Holzhausen HJ, Rath FW, Kuhn H; Peripheral myopathy: a reason for lack of clinical improvement after transcoronary ablation of septal hypertrophy in
patients with HOCM; J Heart Disease Vol.2(1); (2001): 227
Beer G, Gabbert HE, Gietzen FH, Lieder F., Kuhn H; Incidental diagnosis of Fabry`s disease in a patient with HOCM not responding to catheter interventional treatment; European
Heart J., Vol.22, (2001):p407
Kuhn H, Gietzen FH, Breithardt G, Roehrig FR, Lieder F., Goetsch U, Schulte HD, Freick M; Pacemaker therapy and alcohol ablation for HOCM: a randomized study; European Heart J.,
Vol.22, (2001):p407.
Kuhn H, Gietzen FH, Leuner C, Schaefers M, Schober O, Strunk-Müller C, Obergassel L, Freick M, Gockel B, Lieder F., Raute-Kreinsen U; Transcoronary ablation of septal hypertrophy
(TASH): a new treatment option for hypertrophic obstructive cardiomyopathy; Z Kardiol 89;IV/41-IV/54,2000
Lieder F., Gietzen FH, Holzhausen HJ, Rath FW, Kuhn H; Periphere Myopathie - Ein limitierender Faktor für erfolgreiche transkoronare Ablation der Septumhypertrophie (TASH) bei
Patienten mit hypertrophisch obstruktiver Kardiomyopathie (HOCM); Z Kardiol 89; VI/29,2000
Beer G, Gabbert HE, Reinecke P, Gietzen FH, Strunk-Müller C, Lieder F., Kuhn H; Morbus Fabry als bioptischer Zufallsbefund bei einem Patienten mit hypertrophisch obstruktiver
Kardiomyopathie (HOCM); Z Kardiol 89; VI/31,2000
Kuhn H, Gietzen F, Leuner C, Obergassel L, Lieder F., Strunk-Mueller C; Transcoronary ablation of septal hypertrophy (TASH) for HOCM: an alternative to surgical and to pacemaker
therapy; J. Heart Failure,Vol 6(1), July 2000
Kuhn H, Gietzen F, Lerch M, Lieder F., Kruse J; The impact of exercise Doppler echocardiography in patients treated by transcoronary ablation of septal hypertrophy for
hypertrophic obstructive cardiomyopathy; European Heart J, Vol.21;(2000):58
Lieder F., Gietzen FH, Holzhausen HJ, Rath FW, Kuhn H; Peripheral myopathy: a reason for lack of clinical improvement after transcoronary ablation of septal hypertrophy in
patients with HOCM; Cor Vasa 2000;42(7); K152
Beer G, Gabbert HE, Reinecke P, Gietzen FH, Strunk-Müller C, Lieder F., Kuhn H; Incidental diagnosis of Fabry`s disease in a patient with HOCM not responding to catheter
interventional treatment; Cor Vasa 2000;42(7); K142
Lieder F., Brisse B, Borggrefe M, Kerber S, Deng M, Scheld HH, Breithardt G; Edotheliumdependent coronary artery response to cold pressor test after heart transplatation;
Cardiov. Drugs and Ther., Volume 11, June 1997
Lieder F., Brisse B, Lamp B, Fechtrup C, Borggrefe M, Kerber S, Deng M, Scheld HH, Breithardt G; Coronary vasomotion in response to sympathetic stimulation by the cold pressor
test (CPT) after heart transplantation; Intern. Angiol., Vol.16(3), 1997